Compare, Analyse Dishman Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ACTAVIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ACTAVIS
Dec-18
DISHMAN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37414,449-   
Low Rs1299,692-   
Sales per share (Unadj.) Rs197.83,544.2-  
Earnings per share (Unadj.) Rs21.2-1,141.6-  
Cash flow per share (Unadj.) Rs34.7373.5-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.914,618.3-  
Shares outstanding (eoy) m80.69332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.4%   
Avg P/E ratio x11.9-10.6 -112.2%  
P/CF ratio (eoy) x7.232.3 22.4%  
Price / Book Value ratio x1.40.8 169.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3064,014,617 0.5%   
No. of employees `0000.816.9 4.9%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.769,752.4 27.6%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1-22,467.3 -9.2%   
INCOME DATA
Net Sales Rs m15,9611,178,815 1.4%  
Other income Rs m26522,543 1.2%   
Total revenues Rs m16,2261,201,358 1.4%   
Gross profit Rs m4,10330,891 13.3%  
Depreciation Rs m1,091503,918 0.2%   
Interest Rs m94468,024 1.4%   
Profit before tax Rs m2,334-518,508 -0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0132,241 0.0%   
Tax Rs m624-6,571 -9.5%   
Profit after tax Rs m1,711-379,697 -0.5%  
Gross profit margin %25.72.6 981.0%  
Effective tax rate %26.71.3 2,108.7%   
Net profit margin %10.7-32.2 -33.3%  
BALANCE SHEET DATA
Current assets Rs m11,018483,488 2.3%   
Current liabilities Rs m9,517427,710 2.2%   
Net working cap to sales %9.44.7 198.7%  
Current ratio x1.21.1 102.4%  
Inventory Days Days11020 564.2%  
Debtors Days Days3566 52.5%  
Net fixed assets Rs m16,304133,435 12.2%   
Share capital Rs m1610-   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5164,862,062 0.3%   
Long term debt Rs m4,1891,712,108 0.2%   
Total assets Rs m29,8057,600,510 0.4%  
Interest coverage x3.5-6.6 -52.4%   
Debt to equity ratio x0.30.4 82.0%  
Sales to assets ratio x0.50.2 345.3%   
Return on assets %8.9-4.1 -217.3%  
Return on equity %11.8-7.8 -150.9%  
Return on capital %17.5-4.8 -362.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786421,146 0.7%  
From Investments Rs m-1,529231,365 -0.7%  
From Financial Activity Rs m-941-722,813 0.1%  
Net Cashflow Rs m316-69,951 -0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.67 Rs / USD

Compare DISHMAN PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: BIOCON   WOCKHARDT  SHASUN PHARMA  DR. DATSONS LABS  ELDER PHARMA  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views On News

Most Popular

A Critical Update on the Market (Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers (Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS